Stempoint Capital LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Stempoint Capital LP reported 48 stock positions worth $398.7 million. Its top holding was Syndax Pharmaceuticals (SNDX) at 9.5% of the portfolio, followed by Roivant Sciences (ROIV, 8.0%) and Immunovant (IMVT, 6.9%). Compared with Q3 2024, it opened 22 new positions, sold out of 24, added to 19 and reduced 6. The biggest buy was a new position in Xenon Pharmaceuticals (XENE) and the biggest sale an exit from Amicus Therapeutics (FOLD).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001952142
- Portfolio Value
- $398.7M (Q4 2024)
- SEC Filing
- 0001420506-25-000514 ↗ filed Feb 14, 2025
Holdings Value
Holdings 48 stocks · $398.7M
| SNDX Syndax Pharmaceuticals Inc. | 9.52% | 2,872,601 | $38.0M | Add +65.9% |
| ROIV Roivant Sciences Ltd. | 8.05% | 2,712,778 | $32.1M | Reduce -2.1% |
| IMVT Immunovant Inc. | 6.95% | 1,118,508 | $27.7M | Add +66.7% |
| MRUS Merus NV | 6.48% | 614,812 | $25.9M | Add +46.0% |
| CRNX Crinetics Pharmaceuticals Inc. | 4.07% | 317,060 | $16.2M | Add +48.3% |
| XENE Xenon Pharmaceuticals Inc. | 3.70% | 375,845 | $14.7M | New |
| INCY Incyte Corp. | 3.35% | 193,623 | $13.4M | Add +49.5% |
| ALKS Alkermes PLC | 3.01% | 416,968 | $12.0M | Add +752.4% |
| DNLI Denali Therapeutics Inc. | 2.99% | 584,328 | $11.9M | Add +107.2% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.92% | 208,016 | $11.6M | Add +404.1% |
| NUVL Nuvalent Inc. Class A | 2.85% | 145,234 | $11.4M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 2.70% | 641,964 | $10.8M | Add +667.3% |
| PRAX Praxis Precision Medicines I | 2.59% | 134,178 | $10.3M | Reduce -22.9% |
| BMY Bristol-Myers Squibb Co. | 2.36% | 166,068 | $9.4M | Reduce -39.7% |
| WVE Wave Life Sciences Ltd. | 2.24% | 721,209 | $8.9M | Add +140.4% |
| RVMD Revolution Medicines Inc. | 2.12% | 193,535 | $8.5M | Add +1062.1% |
| KALV Kalvista Pharmaceuticals Inc. | 2.11% | 992,803 | $8.4M | New |
| JANX Janux Therapeutics Inc. | 1.96% | 145,876 | $7.8M | Add +195.2% |
| INSM Insmed Inc. | 1.85% | 106,610 | $7.4M | New |
| SRRK Scholar Rock Holding Corp. | 1.80% | 166,307 | $7.2M | New |
| IOVA Iovance Biotherapeutics Inc. | 1.76% | 949,401 | $7.0M | New |
| BNTX Biontech SE-ADR | 1.75% | 61,403 | $7.0M | New |
| ARQT Arcutis Biotherapeutics Inc. | 1.75% | 500,966 | $7.0M | Reduce -71.8% |
| BHVN Biohaven Ltd. | 1.75% | 186,413 | $7.0M | Reduce -13.9% |
| VTGN Vistagen Therapeutics Inc. | 1.49% | 2,328,492 | $5.9M | Add +26.1% |
| PTGX Protagonist Therapeutics Inc. | 1.37% | 141,714 | $5.5M | New |
| SLRN Acelyrin Inc. | 1.34% | 1,704,825 | $5.4M | Add +29.4% |
| SRZN Surrozen Inc. | 1.26% | 350,573 | $5.0M | Add +91.7% |
| MLYS Mineralys Therapeutics Inc. | 1.24% | 400,101 | $4.9M | New |
| NMRA Neumora Therapeutics Inc. | 1.14% | 428,137 | $4.5M | New |
| EYPT Eyepoint Inc. | 1.08% | 579,500 | $4.3M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 1.07% | 101,809 | $4.3M | New |
| ETNB 89BIO Inc. | 1.07% | 545,800 | $4.3M | New |
| CYTK Cytokinetics Inc. | 0.99% | 83,576 | $3.9M | Add +477.8% |
| CTNM Contineum Therapeutics Inc. Class A | 0.98% | 265,833 | $3.9M | New |
| EWTX Edgewise Therapeutics Inc. | 0.89% | 132,706 | $3.5M | Add +566.9% |
| RCKT Rocket Pharmaceuticals Inc. | 0.85% | 270,983 | $3.4M | New |
| JSPR Jasper Therapeutics Inc. | 0.73% | 135,244 | $2.9M | New |
| TRML Tourmaline Bio Inc. | 0.64% | 126,400 | $2.6M | Add +127.7% |
| ELVN Enliven Therapeutics Inc. | 0.55% | 96,716 | $2.2M | New |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.53% | 200,900 | $2.1M | Add +0.5% |
| TARA Protara Therapeutic Inc. | 0.44% | 332,394 | $1.8M | Reduce -64.8% |
| QURE Uniqure NV | 0.40% | 90,000 | $1.6M | New |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.38% | 150,000 | $1.5M | No change |
| VRNA Verona Pharma Ltd. | 0.33% | 28,136 | $1.3M | New |
| CDTX Cidara Therapeutics Inc. | 0.32% | 47,642 | $1.3M | New |
| ATYR Atyr Pharma Inc. | 0.18% | 200,475 | $726K | New |
| TECX Tectonic Therapeutic Inc. | 0.11% | 9,434 | $436K | New |
Options reported separately and not counted above: ARQT calls ($581K), QQQ puts ($515K), SPY puts ($414K), SRRK calls ($228K), HIMS calls ($75K), SNDX calls ($51K).
Portfolio Sells Q3 2024 → Q4 2024
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −4.75 |
| APLT Applied Therapeutics Inc. | Sold out | 0.00% | −3.96 |
| ARQT Arcutis Biotherapeutics Inc. | Reduce -71.8% | 1.75% | −3.21 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −2.85 |
| DAWN Day One Biopharmaceuticals I | Sold out | 0.00% | −2.12 |
| BMY Bristol-Myers Squibb Co. | Reduce -39.7% | 2.36% | −1.92 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −1.87 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −1.81 |
| IMTX Immatics NV | Sold out | 0.00% | −1.54 |
| ROIV Roivant Sciences Ltd. | Reduce -2.1% | 8.05% | −1.54 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −1.51 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −1.50 |
| BHVN Biohaven Ltd. | Reduce -13.9% | 1.75% | −1.50 |
| NRIX Nurix Therapeutics Inc. | Sold out | 0.00% | −1.37 |
| TCRX Tscan Therapeutics Inc. | Sold out | 0.00% | −1.29 |
| ZURA Zura Bio Ltd. | Sold out | 0.00% | −1.27 |
| IDYA Ideaya Biosciences Inc. | Sold out | 0.00% | −1.26 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −1.12 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.95 |
| PYXS Pyxis Oncology Inc. | Sold out | 0.00% | −0.94 |
| NGNE Neurogene Inc. | Sold out | 0.00% | −0.92 |
| URGN Urogen Pharma Ltd. | Sold out | 0.00% | −0.92 |
| VIGL Vigil Neuroscience Inc. | Sold out | 0.00% | −0.76 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −0.72 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −0.56 |
| CAPR Capricor Therapeutics Inc. | Sold out | 0.00% | −0.43 |
| PRAX Praxis Precision Medicines I | Reduce -22.9% | 2.59% | −0.41 |
| MBX MBX Biosciences Inc. | Sold out | 0.00% | −0.39 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −0.19 |
| TARA Protara Therapeutic Inc. | Reduce -64.8% | 0.44% | −0.08 |
Portfolio Buys Q3 2024 → Q4 2024
| XENE Xenon Pharmaceuticals Inc. | New | 3.70% | +3.70 |
| NUVL Nuvalent Inc. Class A | New | 2.85% | +2.85 |
| ALKS Alkermes PLC | Add +752.4% | 3.01% | +2.60 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +667.3% | 2.70% | +2.30 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +404.1% | 2.92% | +2.27 |
| KALV Kalvista Pharmaceuticals Inc. | New | 2.11% | +2.11 |
| RVMD Revolution Medicines Inc. | Add +1062.1% | 2.12% | +1.90 |
| INSM Insmed Inc. | New | 1.85% | +1.85 |
| SRRK Scholar Rock Holding Corp. | New | 1.80% | +1.80 |
| IOVA Iovance Biotherapeutics Inc. | New | 1.76% | +1.76 |
| BNTX Biontech SE-ADR | New | 1.75% | +1.75 |
| WVE Wave Life Sciences Ltd. | Add +140.4% | 2.24% | +1.50 |
| PTGX Protagonist Therapeutics Inc. | New | 1.37% | +1.37 |
| JANX Janux Therapeutics Inc. | Add +195.2% | 1.96% | +1.29 |
| MLYS Mineralys Therapeutics Inc. | New | 1.24% | +1.24 |
| IMVT Immunovant Inc. | Add +66.7% | 6.95% | +1.21 |
| NMRA Neumora Therapeutics Inc. | New | 1.14% | +1.14 |
| EYPT Eyepoint Inc. | New | 1.08% | +1.08 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 1.07% | +1.07 |
| ETNB 89BIO Inc. | New | 1.07% | +1.07 |
| CTNM Contineum Therapeutics Inc. Class A | New | 0.98% | +0.98 |
| RCKT Rocket Pharmaceuticals Inc. | New | 0.85% | +0.85 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +48.3% | 4.07% | +0.79 |
| INCY Incyte Corp. | Add +49.5% | 3.35% | +0.79 |
| CYTK Cytokinetics Inc. | Add +477.8% | 0.99% | +0.76 |
| EWTX Edgewise Therapeutics Inc. | Add +566.9% | 0.89% | +0.73 |
| JSPR Jasper Therapeutics Inc. | New | 0.73% | +0.73 |
| SRZN Surrozen Inc. | Add +91.7% | 1.26% | +0.60 |
| ELVN Enliven Therapeutics Inc. | New | 0.55% | +0.55 |
| DNLI Denali Therapeutics Inc. | Add +107.2% | 2.99% | +0.52 |
| QURE Uniqure NV | New | 0.40% | +0.40 |
| VRNA Verona Pharma Ltd. | New | 0.33% | +0.33 |
| CDTX Cidara Therapeutics Inc. | New | 0.32% | +0.32 |
| TRML Tourmaline Bio Inc. | Add +127.7% | 0.64% | +0.21 |
| ATYR Atyr Pharma Inc. | New | 0.18% | +0.18 |
| MRUS Merus NV | Add +46.0% | 6.48% | +0.17 |
| TECX Tectonic Therapeutic Inc. | New | 0.11% | +0.11 |
| VTGN Vistagen Therapeutics Inc. | Add +26.1% | 1.49% | +0.02 |
| BBOT Bridgebio Oncology Therapeut | Add +0.5% | 0.53% | −0.10 |
| SNDX Syndax Pharmaceuticals Inc. | Add +65.9% | 9.52% | −0.47 |
| SLRN Acelyrin Inc. | Add +29.4% | 1.34% | −0.61 |
Options Activity Q3 2024 → Q4 2024
| ARQT Arcutis Biotherapeutics Inc. | call | Add +530.0% | 1,575,000 | $581K |
| QQQ Invesco QQQ Trust Series 1 | put | New | 70,000 | $515K |
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 85,000 | $414K |
| SRRK Scholar Rock Holding Corp. | call | New | 100,000 | $228K |
| IMVT Immunovant Inc. | call | Sold out | 200,000 | $113Kbefore exit |
| APLT Applied Therapeutics Inc. | call | Sold out | 251,600 | $75Kbefore exit |
| HIMS Hims & Hers Health Inc. | call | New | 75,000 | $75K |
| SNDX Syndax Pharmaceuticals Inc. | call | Add +1.8% | 234,100 | $51K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 73 | $577.9M | TNGX, ABVX, RVMD, ERAS, TYRA |
| Q1 2026Amended | 70 | $520.3M | SRRK, ABVX, SNDX, RVMD, IMVT |
| Q4 2025 | 75 | $582.7M | ABVX, SRRK, CNTA, SNDX, GPCR |
| Q3 2025 | 76 | $495.9M | ROIV, QURE, SRRK, IMVT, DNLI |
| Q2 2025 | 50 | $310.6M | SNDX, IMVT, SRRK, CNTA, MDGL |
| Q1 2025 | 52 | $313.1M | ROIV, SNDX, SRRK, ACLX, MRUS |
| Q4 2024 | 48 | $398.7M | SNDX, ROIV, IMVT, MRUS, CRNX |
| Q3 2024 | 50 | $333.4M | SNDX, ROIV, MRUS, IMVT, ARQT |
| Q2 2024Amended | 42 | $339.9M | SNDX, ROIV, IMVT, CRNX, MRUS |
| Q1 2024Amended | 45 | $374.3M | ROIV, CRNX, SNDX, ARQT, IMVT |